3 BIOTECH STOCKS WALL STREET ANALYSTS PREDICT WILL MORE THAN DOUBLE
https://s.yimg.com/ny/api/res/1.2/D0kk7k5hhBRzXkRz6aQMRg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzU-/https://media.zenfs.com/en/barchart_com_477/99166d40b80d8f9827374af99e9e70d8
✍️ The biotech industry is an exciting investment prospect, with the sector projected to reach $3.9 trillion by 2030 and $8 trillion by 2035. Despite recent setbacks, three biotech stocks, DiaMedica Therapeutics, GH Research, and Tyra Biosciences, are considered strong buys by Wall Street analysts.
👉 DiaMedica Therapeutics is developing DM199 for ischemic disorders, with a market cap of $380 million and a potential upside of 242.5% 👉 GH Research is developing therapies for psychiatric/neurological disorders, with a market cap of $748 million and a potential upside of 112.1% 👉 Tyra Biosciences is developing precision medicines targeting Fibroblast Growth Factor Receptor (FGFR) biology, with a market cap of $887 million and a potential upside of 89.5%
-- #Dublin,Ireland #biotech
Loading quoted post…
